Table 2 Patient-reported outcomes at baseline, post-intervention (RealRisks) and at 6 months or after the clinical encounter with their primary care providers
Patient Outcome Measures | Baseline (T0) | Post-RealRisks (T1) | Post-Clinical Encounter or 6 months (T2) | p-value | ||
|---|---|---|---|---|---|---|
|  | (N = 40) | (N = 37) | (N = 32) | T0-T1 | T0-T2 | T1-T2 |
Breast Cancer Risk Perception | ||||||
 Mean difference between perceived and actual lifetime breast cancer risk (SD) | 23.67 (24.68) | 12.09 (18.13) | 20.35 (27.65) | 0.01 | 0.36 |  |
 Accurate breast cancer risk perception, N(%) | 15 (39.47) | 23 (63.89) | 20 (62.50) | 0.02 | 0.02 |  |
Breast cancer knowledge | ||||||
 Mean number correct (SD) [range, 0–15] | 8.00 (1.69) | 8.59 (1.38) | 7.94 (1.90) | 0.10 | 0.14 |  |
 Adequate knowledge, N (%) | 25 (64.10) | 30 (81.08) | 17 (53.13) | 0.13 | .32 |  |
Chemoprevention knowledge | ||||||
 Mean number correct (SD) [range, 0–8] | 0.71 (1.46) | 3.69 (2.39) | 1.94 (1.92) | <.01 | <.01 |  |
 Adequate knowledge, N (%) | 4 (10.53) | 18 (50.00) | 9 (28.13) | < 0.01 | 0.10 |  |
 Mean breast cancer worry (SD) [range, 1–7] | 3.17 (1.80) | 3.66 (2.17) | 3.30 (2.06) | 0.17 | 0.75 |  |
 Mean self-efficacy in chemoprevention (SD) [range, 0–100] | 56 (15.81) | 60.22 (15.45) |  | 0.24 |  |  |
 Mean decision conflict (SD) [range, 0–100] |  | 17.92 (19.51) | 43.44 (31.30) |  |  | <.01 |
Decision conflict, N (%) | <.01 | |||||
 Decision implementation (< 25) |  | 23 (63.9) | 9 (28.1) |  |  |  |
 Unsure about implementation (25–37.5) |  | 5 (13.9) | 5 (15.6) |  |  |  |
 Decision delay (> 37.5) |  | 8 (22.2) | 18 (56.3) |  |  |  |
Decision conflict sub-scores (SD) (range, 0–100) | ||||||
 Informed subscore |  | 9.03 (12.66) | 24.48 (19.74) |  |  | <.01 |
 Values clarity subscore |  | 8.33 (15.24) | 23.44 (20.02) |  |  | <.01 |
 Support subscore |  | 7.87 (9.33) | 17.71 (18.66) |  |  | 0.01 |
Chemoprevention intention, N (%) | ||||||
 Yes |  | 9 (24.3) |  |  |  |  |
 No |  | 12 (32.4) |  |  |  |  |
 Unsure |  | 17 (45.9) |  |  |  |  |
High-risk referrals, N (%) | Â | Â | 3 (7.5) | Â | Â | Â |
Chemoprevention uptake, N (%) 0 | ||||||